Dec. 23, 2013:

University of Nebraska Medical Center‘s Julie Vose, M.D., has been elected president of the American Society of Clinical Oncology (ASCO) for a one-year term beginning in June 2015.

Vose will take office as president-elect during the ASCO annual meeting in Chicago in June 2014.

“ASCO is a very diverse and multifaceted organization with so much to offer its membership,” Vose said. “I am excited to serve the ASCO membership as president and to make a difference for oncology professionals and our patients.”

Vose cited the recent enhancements in the society’s educational offerings, quality improvement, and broadened advocacy as areas where her experience and training can add to the current ASCO activities, including CancerLinQ(TM), ASCO’s groundbreaking health information technology initiative to achieve higher quality, higher value cancer care with better outcomes for patients.

Ken Cowan, M.D., Ph.D., director of the Fred & Pamela Buffett Cancer Center, called the election a great honor for Vose and UNMC.

“She is an internationally recognized leader in clinical trials in lymphoma,” he said. “As the leader of the largest organization of clinical oncologists, she will be able to have a major impact on the future directions of clinical research and clinical care in cancer.”

Vose’s election and involvement in ASCO and other national oncology organizations are a credit to UNMC as well as Vose, said James Armitage, M.D., the Joe Shapiro Professor of Internal Medicine in the UNMC Division of Oncology/Hematology.

“I’m incredibly proud of Julie and what she’s accomplished,” Armitage said. “This is the most visible and one of the most important oncology positions in the world. It reflects her excellence in clinical medicine and research.”

Vose is the Neumann M. and Mildred E. Harris Professorial Chair and chief of the oncology/hematology division in the UNMC Department of Internal Medicine, as well as the associate director of clinical research and co-chair of the lymphoma program at the Fred & Pamela Buffett Cancer Center. Since joining ASCO in 1991, she has served on the board of directors, as chair of the Cancer Education Committee and is the current chair-elect of the Integrated Media and Technology Committee, among other activities.

ASCO’s board of directors is comprised of oncology leaders who are elected to positions reflecting various specialties within the oncology field.

— Reposted with permission from University of Nebraska Medical Center.

The Big Ten Cancer Research Consortium creates a unique team-research culture to drive science rapidly from ideas to treatment-changing paradigms. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in student-athletes’ lives and emphasize the values of integrity, fairness and competitiveness. The broad-based athletic programs of the 12 Big Ten institutions provide in excess of $141 million in direct financial aid to more than 8,200 student-athletes playing on more than 300 teams in 43 different sports. The Big Ten sponsors 26 official conference sports, 13 for men and 13 for women, and will add men’s and women’s lacrosse as the 27th and 28th official sports for the 2014-15 academic year. For more information, visit www.bigten.org.